Stocktoria
YD Bio Ltd YDES
YD Bio Ltd (YDES) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $596,817 at a -1392.6% net margin.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.583 |
| Retained earnings / assets | -0.743 |
| EBIT / assets | -0.383 |
| Equity / liabilities | -0.172 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| YDES | YD Bio Ltd | 1/9 | -1.35 | — | — |
| SERA | SERA PROGNOSTICS, INC. | 2/9 | -8.32 | — | — |
| ACON | Aclarion, Inc. | 4/9 | 4.23 | — | — |
| BGLC | BioNexus Gene Lab Corp | 4/9 | 13.26 | — | — |
| CFOR | CapForce Inc. | 2/9 | -14.09 | 1 | — |
| XGN | EXAGEN INC. | 3/9 | -14.91 | — | +19.7% |
| PSNL | Personalis, Inc. | 3/9 | 0.31 | — | -17.7% |
About YD Bio Ltd
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.
FAQ
Is YDES financially healthy?
YD Bio Ltd's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does YDES pay a dividend?
No, YD Bio Ltd does not currently pay a dividend.
How profitable is YDES?
In FY2025, YD Bio Ltd had a net margin of -1392.6%.
Is YDES a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on YD Bio Ltd: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.